Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study.

Meunier M, Thepot S, Nimubona S, Veloso M, Lefebvre T, Karim Z, Ropert-Bouchet M, Garban F, Amé S, Reynes C, Salanoubat C, Parinet V, Laribi K, Eftekhari P, Delaunay J, Venton G, Santana C, Cheze S, Dimicoli-Salazar S, Toma A, Molimard M, Fenaux P, Rolland-Neyret V, David-Tchouda S, Park S

Open source

DOI: 10.3324/haematol.2026.301420
Published: 2026 Sep 24
Container: Haematologica
Publisher: Not recorded
Open access: unknown

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.3324/haematol.2026.301420,
  title = {Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study.},
  author = {Meunier M and Thepot S and Nimubona S and Veloso M and Lefebvre T and Karim Z and Ropert-Bouchet M and Garban F and Amé S and Reynes C and Salanoubat C and Parinet V and Laribi K and Eftekhari P and Delaunay J and Venton G and Santana C and Cheze S and Dimicoli-Salazar S and Toma A and Molimard M and Fenaux P and Rolland-Neyret V and David-Tchouda S and Park S},
  year = {2026},
  journal = {Haematologica},
  doi = {10.3324/haematol.2026.301420},
  url = {https://doi.org/10.3324/haematol.2026.301420}
}

RIS

TY  - JOUR
TI  - Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study.
AU  - Meunier M
AU  - Thepot S
AU  - Nimubona S
AU  - Veloso M
AU  - Lefebvre T
AU  - Karim Z
AU  - Ropert-Bouchet M
AU  - Garban F
AU  - Amé S
AU  - Reynes C
AU  - Salanoubat C
AU  - Parinet V
AU  - Laribi K
AU  - Eftekhari P
AU  - Delaunay J
AU  - Venton G
AU  - Santana C
AU  - Cheze S
AU  - Dimicoli-Salazar S
AU  - Toma A
AU  - Molimard M
AU  - Fenaux P
AU  - Rolland-Neyret V
AU  - David-Tchouda S
AU  - Park S
PY  - 2026
JO  - Haematologica
DO  - 10.3324/haematol.2026.301420
UR  - https://doi.org/10.3324/haematol.2026.301420
ER  -

APA

M, M., S, T., S, N., M, V., T, L., Z, K., M, R., F, G., S, A., C, R., C, S., V, P., K, L., P, E., J, D., G, V., C, S., S, C., S, D., A, T., M, M., P, F., V, R., S, D., & S, P. (2026). Low-dose deferasirox for lower-risk myelodysplastic syndromes after erythropoiesis-stimulating agents (ESA) failure: results of the phase II LODEFI study.. Haematologica. https://doi.org/10.3324/haematol.2026.301420

Source records

pubmed · retrieved 2026-09-26T04:49:14.818Z